TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01736345

Intervention type: GENETIC
Intervention: Genetic Providers
Description: Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.

Intervention type: GENETIC
Intervention: Genetic Providers
Description: Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.

Intervention type: OTHER
Intervention: Visual Aids
Description: Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.

Intervention type: OTHER
Intervention: Visual Aids
Description: Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.

Intervention type: OTHER
Intervention: Post-Disclosure Asessments
Description: Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.

Intervention type: OTHER
Intervention: Post-Disclosure Asessments
Description: Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.

Intervention type: OTHER
Intervention: In-person Clinical Follow-Up
Description: Participants who receive their test results in person will meet with a Physician, Physician Assistant or Nurse Practitioneras part of their in person disclosure session. Participants randomiZed to telephone disclosure will be recommendedto schedule an in-person clinical follow-up appointment with a Physician, Physician Assistant or Nurse Practitioner

Intervention type: OTHER
Intervention: 6 Month and 12 Month Assessments
Description: At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.

Intervention type: OTHER
Intervention: 6 Month and 12 Month Assessments
Description: At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.
Study: NCT03230058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
Description: instillation of drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
Description: instillation of drops
Study: NCT04338841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOME-CoV rule implementation
Description: HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.~Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments.
Study: NCT01500382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine ER
Description: Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
Study: NCT03749616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
Study: NCT01500382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (vibegron)
Description: Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
Study: NCT03749616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
Study: NCT02711553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Administered IV
Study: NCT01600027

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: Fascia iliaca compartment block was performed as described by Dalens et al technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca block
Description: Fascia iliaca compartment block was performed as described by Dalens et al technique.
Study: NCT03306628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 Laser Administration
Description: The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 Laser Administration
Description: The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
Study: NCT02768727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: drug given in concentrations of 0% to 60% over period of 2 hours
Study: NCT01866111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01634048

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein, low calorie meal replacement
Description: The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: High Protein, low calorie meal replacement
Description: The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
Study: NCT05333601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSCCIP
Description: The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
Study: NCT01102868

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Needle in acupuncture point Li11
Description: Acupuncture needle in acupuncture point Li11

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMS of the musculus pronator teres
Description: Acupuncture needle in musculus pronator teres
Study: NCT05799352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic lung volume reduction
Description: a prospective monocentric study on hyperinflated COPD patients without collateral ventilation. Patients were evaluated before and 3 months after unilateral ELVR by transdiaphragmatic pressure (Pdi) measured at the functional residual capacity (FRC) after magnetic phrenic stimulation and by high-resolution computed tomography at the FRC allowing 3D modelling of the diaphragm for measurements of fibers length, length of the zone of apposition and radius of curvature of the diaphragmatic domes.
Study: NCT04174378

Intervention type: DRUG
Intervention: Decapeptyl 0.2mg
Description: IM Decapeptyl o.2 mg was given 2 days before embryo transfer
Study: NCT02556918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill daily starting one day prior to surgery until discharge from the hospital.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular Human Insulin
Description: Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Study: NCT00167583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha2a
Description: 3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
Study: NCT00472095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fotonovela
Study: NCT03510039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early device / Follow up
Description: Early device:~Standardized Nursing Interview (30 minutes) with the Third Party Person Measure and follow the anxiety of the Third Party by rating the AMDP-AT scale, on D0 and D7~Telephone follow-up by nurses:~Interviews built and standardized, to M2, M4 and M6 Quantification of the AMDP-AT anxiety scale on each call

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Group Before : usual care by nurses
Study: NCT02409199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT00472095

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fotonovela
Study: NCT02409199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Study: NCT01343810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
Study: NCT02556918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: Patients that required continuous insulin infusion (CII) at a rate \>1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between \>180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG \>241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patients that required continuous insulin infusion (CII) at a rate \>1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between \>180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG \>241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal
Study: NCT01343810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
Study: NCT02934698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
Study: NCT04443946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Sevoflurane
Description: add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Sevoflurane continue
Description: 1% sevoflurane continued to maintain anesthesia after endotracheal intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Sevoflurane
Description: 2% sevoflurane continued to maintain anesthesia after endotracheal intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol half
Description: 2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol half
Description: 2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Study: NCT01560234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Single dose, oral inhalation (nebuliser solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, oral inhalation (nebuliser solution)
Study: NCT03929120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Description: Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
Study: NCT00730535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: Extended release tolterodine tartrate 4 mg, once daily, for 1 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: Extended release tolterodine tartrate 4 mg, once daily, for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine 6
Description: Extended release tolterodine tartrate 4 mg, once daily, for 6 months
Study: NCT04519268

Intervention type: DIAGNOSTIC_TEST
Intervention: Adult patients scheduled for an elective general surgical operation.
Description: The anesthesiologist, who is in charge of preoperative assessment at each hospital unit, will assess patients who are scheduled for elective surgery; and will inform senior anesthesiologists (with a minimum 3 years of experience) \& consultant anesthesiologists, about the patients' data.~Patients data with all requested preoperative investigations \& required preparations, peri-operative course and post-operative outcome will be collected.
Study: NCT04033731

Intervention type: BEHAVIORAL
Intervention: Attention Network Task
Description: The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
Study: NCT01509313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hysteroscopic morcellator (TruClear)
Description: It can be used to treat uterine pathology with a mechanical cutting edge

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Electrical resectoscope (Versapoint)
Description: It can be used to treat uterine pathology with an electrical cutting edge